Co-Diagnostics, Inc. CODX shares are trading higher on Thursday.
The company announced that OralDNA Labs, a CLIA-certified laboratory, have validated a COVID-19 PCR test based on the company's patented CoPrimer technology for use with saline oral rinse samples.
Co-Diagnostics a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules.
Co-Diagnostics shares were trading up 37.05% at $13.02 at the time of publication Thursday. The stock has a 52-week high of $21.75 and a 52-week low of 69 cents.
Related Links:
3 Frontrunners In COVID-19 Vaccine Development: What You Need To Know
Co-Diagnostics To Provide Coronavirus Tests To Certified US Labs After FDA Policy Change
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.